Additional Insulin for High Fat/Protein in Type 1 Diabetes

Sponsor
Ege University (Other)
Overall Status
Completed
CT.gov ID
NCT05152121
Collaborator
(none)
20
1
1
30
0.7

Study Details

Study Description

Brief Summary

Aim: Dietary carbohydrate is the predominant macronutrient affecting postprandial blood glucose excursions, dietary fat and protein can also significantly impact the postprandial glycemic profile. The aim of this study is to compare the impact of additional dose of extended insulin bolus; using Pankowsko algorithm (PA) to usual standard carbohydrate counting (CC) on postprandial glucose excursions for high fat /high energy density mixed meal for 12 hours.

Methods: In this single-center, non-blinded, randomized, crossover study a high fat, high energy density test meal containing 80 gram carbohydrate (34%), 70 gram fat (66%) and 35 g protein (14%) was given using standard carbohydrate counting (CC) on the first test day and PA was used for the second test day for the same meal. Two methods were compared on postprandial early (0-120 min), late (120-720 min) and total (0-720 min) glucose response in 20 patients with type 1 diabetes mellitus (T1DM), aged 9-18 years on continuous subcutan insulin infusion (CSII) therapy using continuous glucose monitoring system (CGMS).

Condition or Disease Intervention/Treatment Phase
  • Other: Carb and fat counting
N/A

Detailed Description

Children and adolescents with T1DM between the ages of 9-18 and undergoing insulin infusion pump therapy followed in Ege University Pediatric Endocrinology Department will be randomly selected regardless of metabolic control. The selection of the cases will be made from the beginning of the study as the first 30 patients who meet the research participation criteria and agree to participate in the study. Before the research starts, the cases will be told about the application of CGMS, their responsibilities in the research, and an appointment will be given for the insertion of CGMS and this procedure will be applied to all participants. On the day of the appointment, the participant will be put on CGMS, and as long as CGMS is attached, they will be asked to measure capillary blood glucose in their diaries and record them. The subjects will be checked whether they are within the target blood glucose values for 2 days before consuming the test meal and normoglycemia will be provided. On the first day of the study, a test meal with 80 g carbohydrate (29.3%), 70.2 g fat (57.9%), 34.7 g protein (12.7%), will be consumed in the evening meal and carbohydrate counting-normal bolus insulin will be given by administration. On the second day of the study, the additional insulin for fat and protein will be given as a dual wave bolus instead of the normal bolus for the test meal. Then, CGMS will be extracted from the cases, transferred to the computer, and analysis will be made by the researcher, taking into account the capillary blood glucose measurements in the diary.

Study Design

Study Type:
Interventional
Actual Enrollment :
20 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
The Effect of Fat - Protein Counting on Glycemic Variability in Children and Adolescents With Type 1 Diabetes Mellitus
Actual Study Start Date :
Jul 1, 2017
Actual Primary Completion Date :
Apr 30, 2018
Actual Study Completion Date :
Dec 31, 2019

Arms and Interventions

Arm Intervention/Treatment
Other: carb counting

Patients using insulin infusion pumps will be placed CGMS for 2 days before starting the study to check whether they are within the target blood glucose levels and normoglycemia will be provided. The content of the first day of the study; The test meal, which is 80 g carbohydrate (29.3%), 70.2 g fat (57.9%), 34.7 g protein (12.7%), will be consumed in the evening meal and normal bolus insulin will be given according to carbohydrate counting. On the second day of the study, instead of the normal bolus for the test meal, the additional insulin for fat-protein by dual wave bolus that.The data obtained will be analyzed by evaluating the CGMS data of all patients by a pediatric endocrinologist experienced in diabetes, CGMS and insulin infusion pump therapy.

Other: Carb and fat counting
In the 7 days leading up to the study, participants were contacted to review blood glucose levels with CGMS, food and activity diary. basal rates and insulin carbohydrate ratio and sensitivity factor were changed according to the CGMS values and normoglycemia was achieved.In the study day same meals were served which included high fat, high energy density test meal containing 80 gram carbohydrate (34%), 70 gram fat (66%) and 35 g protein (14%).The participants had to have no glucose fluctuations 2 hours before study entry based on CGMS, no correction boluses for at least 4 hours before the test meal consumption and fasting glycemia in the range of 70-180 mg/dL on both study days.The participants received the test meal calculating insulin dose by CC on the first study day and calculating insulin dose by and fat/protein counting in the second study day. The test meal consumption was completed in 20 minutes under supervision by a caregiver and a dietician of the research team

Outcome Measures

Primary Outcome Measures

  1. AUC [AUC was evaluated the day where only carbs were counted and the day were fat and proteins were counted]

    The primary outcomes were glucose area under the curve (AUC) and % of time spent in normoglycemia according to CC; PA and modified PA algorithms.

Secondary Outcome Measures

  1. hypoglycemia epizode [Hypoglycemia was evaluated the day where only carbs were counted and the day were fat and proteins were counted]

    The secondary outcomes were the number of hypoglycemic events over the study period based on capillary blood glucose measurements.

Eligibility Criteria

Criteria

Ages Eligible for Study:
9 Years to 18 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Children-adolescents with Type 1 DM between the ages of 9-18 and undergoing insulin infusion pump therapy followed by Ege University Faculty of Medicine, Department of Pediatric Endocrine.

  2. Those with a body mass index between -2- + 2 SD

Exclusion Criteria:
  1. Cases that do not accept to fill in the 'Informed Consent Form'

  2. Cases with diseases accompanying T1DM (autoimmune diseases such as celiac, cystic fibrosis, etc.)

  3. Body mass index <-2 SD and> +2 SD

Contacts and Locations

Locations

Site City State Country Postal Code
1 Ege University Faculty of Medicine Department of Pediatrics İzmir Turkey 35100

Sponsors and Collaborators

  • Ege University

Investigators

  • Study Chair: Sukran Darcan, MD Prof, Ege University
  • Principal Investigator: Yasemin Atik Altınok, pHD, Ege University Fac Of Medicine Department of Pediatrics
  • Principal Investigator: Hafize Cetin Işıklar, Nurse, Ege University Fac Of Medicine Department of Pediatrics
  • Principal Investigator: Gunay Demir, MSci Nurse, Ege University Fac Of Medicine Department of Pediatrics
  • Principal Investigator: Samim Ozen, MD,PhD, Ege University Fac Of Medicine Department of Pediatrics

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Yasemin Atik Altinok, Dietician PhD, Ege University
ClinicalTrials.gov Identifier:
NCT05152121
Other Study ID Numbers:
  • 16-12.1/44
First Posted:
Dec 9, 2021
Last Update Posted:
Dec 30, 2021
Last Verified:
Dec 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Yasemin Atik Altinok, Dietician PhD, Ege University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 30, 2021